SG11202001595SA - Angio-3 for treatment of retinal angiogenic diseases - Google Patents
Angio-3 for treatment of retinal angiogenic diseasesInfo
- Publication number
- SG11202001595SA SG11202001595SA SG11202001595SA SG11202001595SA SG11202001595SA SG 11202001595S A SG11202001595S A SG 11202001595SA SG 11202001595S A SG11202001595S A SG 11202001595SA SG 11202001595S A SG11202001595S A SG 11202001595SA SG 11202001595S A SG11202001595S A SG 11202001595SA
- Authority
- SG
- Singapore
- Prior art keywords
- angio
- treatment
- angiogenic diseases
- retinal angiogenic
- retinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553051P | 2017-08-31 | 2017-08-31 | |
| PCT/IB2018/056685 WO2019043649A2 (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001595SA true SG11202001595SA (en) | 2020-03-30 |
Family
ID=65525123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001595SA SG11202001595SA (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11266710B2 (en) |
| EP (1) | EP3675889A4 (en) |
| JP (1) | JP2020532586A (en) |
| CN (1) | CN111344002A (en) |
| AU (1) | AU2018326835A1 (en) |
| SG (1) | SG11202001595SA (en) |
| WO (1) | WO2019043649A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN112203679A (en) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | IL-6 antibodies and fusion constructs and conjugates thereof |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5902790A (en) | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| NZ307044A (en) * | 1995-04-26 | 2002-03-01 | Childrens Medical Center | Angiostatin fragments with antiangiogenic activity |
| US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
| SG87828A1 (en) * | 1999-09-03 | 2002-04-16 | Univ Singapore | Small peptides having potent anti-angiogenic activity |
| CA2485064A1 (en) * | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Albumin-fused kunitz domain peptides |
| AU2003225910A1 (en) * | 2002-03-20 | 2003-10-08 | Johns Hopkins University | Raav vector compositions and methods for the treatment of choroidal neovascularization |
| CN101942012A (en) * | 2009-07-08 | 2011-01-12 | 上海市第一人民医院 | Polypeptide for preventing and treating angiogenesis and application thereof |
| ES2606627T3 (en) * | 2010-05-28 | 2017-03-24 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Specific anti-CD160 antibodies for the treatment of eye disorders based on neoangiogenesis |
| UY35195A (en) | 2012-12-18 | 2014-07-31 | Novartis Ag | COMPOSITIONS AND METHODS FOR PROLINED ACTION PROTEINS |
| SG11201602889TA (en) * | 2013-10-28 | 2016-05-30 | Bicycle Therapeutics Ltd | Novel polypeptides |
-
2018
- 2018-08-31 AU AU2018326835A patent/AU2018326835A1/en not_active Abandoned
- 2018-08-31 US US16/641,978 patent/US11266710B2/en active Active
- 2018-08-31 WO PCT/IB2018/056685 patent/WO2019043649A2/en unknown
- 2018-08-31 SG SG11202001595SA patent/SG11202001595SA/en unknown
- 2018-08-31 CN CN201880056661.2A patent/CN111344002A/en active Pending
- 2018-08-31 EP EP18851201.6A patent/EP3675889A4/en not_active Withdrawn
- 2018-08-31 JP JP2020533879A patent/JP2020532586A/en active Pending
-
2021
- 2021-11-12 US US17/525,793 patent/US20220175876A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020532586A (en) | 2020-11-12 |
| EP3675889A4 (en) | 2021-05-12 |
| US20200246417A1 (en) | 2020-08-06 |
| WO2019043649A3 (en) | 2019-05-02 |
| WO2019043649A2 (en) | 2019-03-07 |
| AU2018326835A1 (en) | 2020-03-26 |
| US20220175876A1 (en) | 2022-06-09 |
| EP3675889A2 (en) | 2020-07-08 |
| US11266710B2 (en) | 2022-03-08 |
| CN111344002A (en) | 2020-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276383A (en) | Treatment of ophthalmologic diseases | |
| PT3122878T (en) | Mrna therapy for the treatment of ocular diseases | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
| SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| IL269698B (en) | Methods of preventing or treating ophthalmic diseases | |
| ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
| IL270362B (en) | Treatment of glaucoma | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| ZA202002910B (en) | Treatment of skin disorders | |
| SMT202100070T1 (en) | Complex and compositions for the treatment of ophthalmic and dermatological diseases | |
| IL263837A (en) | Treatment of ocular disease | |
| HK40033084A (en) | Angio-3 for treatment of retinal angiogenic diseases | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| GB201705435D0 (en) | Treatment of ocular disease | |
| PL3710043T3 (en) | Fgf10 for the treatment of heart diseases | |
| GB201811911D0 (en) | Treatment of disease | |
| GB201811912D0 (en) | Treatment of disease | |
| GB201810974D0 (en) | Treatment of disease | |
| GB201805556D0 (en) | Treatment of ophthalmological conditions | |
| GB201610938D0 (en) | Treatment of ocular disease | |
| GB201706662D0 (en) | Treatment of neurological diseases | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201614076D0 (en) | Diagnosis and treatment of ocular disorders |